Shelley Jeon

P4 pharmacy student @northeastern

[Shelley Jeon @ShelleyJeon]

Today was Day 2 of my infectious disease rotation @BrighamWomens. After each day, I will share a "one thing I learned today (#OTILT)".

Super excited to learn from my preceptors @BWDionne @jeffpears0n @davidwkubiak and with my co-APPE students @SikandarIDAPPE @_michelleyu 🦠💊

[Shelley Jeon @ShelleyJeon]

@BWDionne @davidwkubiak @jeffpears0n
@SikandarIDAPPE @_michelleyu

Thank you for a great rotation 🥳 It was a privilege to work with you all!

[Shelley Jeon @ShelleyJeon]

#OTILT β-lactam antibiotics should not be administered intraventricularly due to high potential to induce epileptic seizures.

Source: https://t.co/pCo4jwHa6l

[Shelley Jeon @ShelleyJeon]

Reference:
https://t.co/mZ2d82iYTH
https://t.co/xLh9HYWsEg

@BWDionne @davidwkubiak @jeffpears0n
@SikandarIDAPPE @_michelleyu

[Shelley Jeon @ShelleyJeon]

#OTILT Cefazolin & ertapenem can be used for persistent MSSA bacteremia. The synergy is thought to be d/t complimentary PBP-binding sites—ertapenem for PBP 1 and cefazolin for PBP 2. Another thought is that the combo stimulates IL-1β release, improving the host immune response.

[Shelley Jeon @ShelleyJeon]

References:
https://t.co/Dcv4IrTf8A
https://t.co/KZTvG5Rzlm

@BWDionne @davidwkubiak @jeffpears0n @SikandarIDAPPE @_michelleyu

[Shelley Jeon @ShelleyJeon]

#OTILT There are antibiotic stewardship program (ASP) requirements for all @TJCommission-accredited hospitals. @CMSGov also requires all acute-care hospitals that participate in Medicare or Medicaid to have ASPs in order to receive CMS payments.

[Shelley Jeon @ShelleyJeon]

References
https://t.co/o5PzkP8hvE
https://t.co/jW6CWqn2eB

@BWDionne @jeffpears0n @davidwkubiak
@SikandarIDAPPE @_michelleyu

[Shelley Jeon @ShelleyJeon]

#OTILT There is no vaccine available for Lyme disease.

LYMErix was the only Lyme vaccine ever brought to the US market, and it was voluntarily withdrawn by the manufacturer in 2002 due to declining sales amidst poor media coverage and fears of vaccine SEs (e.g., arthritis).

[Shelley Jeon @ShelleyJeon]

Reference: https://t.co/RR4XQVHfRH

@BWDionne @jeffpears0n @davidwkubiak @SikandarIDAPPE @_michelleyu

[Shelley Jeon @ShelleyJeon]

#OTITL This study found that once daily BIC/FTC/TAF (Biktarvy) maintained virologic suppression in PLWH on chronic HD (n = 10) through 48 weeks. This may be a safe, effective, and convenient ART option in PLWH on chronic HD.

[Shelley Jeon @ShelleyJeon]

Reference: https://t.co/nqrwlM5Wb1

@BWDionne @jeffpears0n @davidwkubiak
@SikandarIDAPPE @_michelleyu

[Shelley Jeon @ShelleyJeon]

#OTILT The four phases of chronic HBV are:
(1) immune tolerant
(2) HBeAg-positive chronic hepatitis
(3) inactive carrier
(4) HBeAg-negative chronic hepatitis

Each phase is defined by HBeAg status, serum HBV DNA, and ALT levels.

[Shelley Jeon @ShelleyJeon]

Reference: https://t.co/Znu9gzrkDY

@BWDionne @jeffpears0n @davidwkubiak
@SikandarIDAPPE @_michelleyu

[Shelley Jeon @ShelleyJeon]

#OTILT The PROPHY-VAP trial (n = 319) recently found that in patients with acute brain injury, a single dose of IV ceftriaxone 2 g within 12h of tracheal intubation reduced the risk of early VAP by 40%.

[Shelley Jeon @ShelleyJeon]

References:
https://t.co/NUruGzIjMh
https://t.co/hx2sUwStSr

@BWDionne @jeffpears0n
@davidwkubiak @SikandarIDAPPE @_michelleyu

[Shelley Jeon @ShelleyJeon]

#OTILT MAT2203 is an oral, encochleated form of amphotericin B (CAmB) manufactured by @MatinasBio that is being studied in a Phase 2 clinical trial for cryptococcal meningitis. Earlier clinical trials of MAT2203 have shown similar survival and less toxicity than IV AmB.

[Shelley Jeon @ShelleyJeon]

References:
Lactic acidosis - https://t.co/JL5NqBEBaQ
Myelosuppression - https://t.co/N9s5c2ClS9
Peripheral neuropathy - https://t.co/Vndyt6iR8s

@BWDionne @jeffpears0n @davidwkubiak @SikandarIDAPPE @_michelleyu

[Shelley Jeon @ShelleyJeon]

#OTILT Prolonged use of linezolid has been associated w/ reversible myelosuppression (most commonly thrombocytopenia), lactic acidosis, and potentially irreversible peripheral and optic neuropathy.

[Shelley Jeon @ShelleyJeon]

STOP-IT trial (2015): https://t.co/AsVSODVawd
DURAPOP trial (2018): https://t.co/J8IIaUi8UT

@BWDionne @jeffpears0n @davidwkubiak
@SikandarIDAPPE @_michelleyu

Happy Friday, everyone! 🥳

[Shelley Jeon @ShelleyJeon]

#OTILT In 2015, the STOP-IT trial found similar outcomes when comparing ~4 vs. ~8 days of abx for intraabdominal infections (IAI) w/ adequate source control. 3 years later, the DURAPOP trial found similar outcomes between 8 vs. 15 days of abx in critically ill post-op IAI pts.